EQS — News: Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026
EQS-News: Heidelberg Pharma AG / Key word(s): Study results Heidelberg Pharma Presented New Clinical Data for Lead ATAC Candidate Pamlectabart Tismanitin at IMS Annual Meeting 2026 24.09.2026 / 10:33 CET/CEST The issuer is solely responsible for the content of this announcement. ════════════════════════════════════════